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Tragedy of the uncommon
Mediawatch: Bernard Dixon looks at the response of the British media 
to the disastrous reactions of volunteers in the recent first clinical trial of 
a new drug in London.On 13 March six men were 
admitted to intensive care at 
Northwick Park Hospital, London, 
after suffering severe reactions 
while taking part in a phase 1 
clinical trial of an experimental 
drug in a research unit run at the 
hospital by US-owned Parexel 
International, a contract research 
company. Two days later, the story 
hit the front pages, as successive 
editions of the London Evening 
Standard announced “Guinea Pig 
Drug Students In Fight For Life” 
and “Drugs Victim Left Like The 
Elephant Man”. The Daily Mail 
trumpeted “Hell Of Human Guinea 
Pigs”.
In the days following, The 
Sun in particular highlighted the 
human story. “Ryan was a healthy 
young man and he saw the trial 
advertised on the internet. He 
is at college and was doing it to 
make a bit of extra money,” a 
family friend had said. “He told 
us he would be paid £2000 and 
did not think there would be any 
problems. His mother got a call 
last night to say his head and 
neck were swelled up and his legs 
had turned purple.”
“Give us answers, demand 
families,” added the Daily Mail. 
Alongside a photograph of “the 
one who got away” (a volunteer 
given placebo) a caption read 
“They were writhing, screaming, 
burning up and begging for help.” 
Virtually ignoring the story itself, 
the Daily Mirror allocated a whole 
page to “The Vulture – Exposed…
hospital porter who tried to sell 
pictures of the drug trial victims”.
For the most part, journalists 
from right across the media 
spectrum worked hard and quickly 
to determine the underlying facts 
about the trial, and to explain the 
various ways in which it might 
have gone awry. The “drug” was 
in fact an immunomodulatory 
humanised agonistic CD28 
monoclonal antibody, TGN 1412, developed by the company 
TeGenero at the University of 
Wurzburg in Germany. Its purpose 
was to bind to and activate killer 
T cells, as a possible means of 
treating leukaemia, rheumatoid 
arthritis and multiple sclerosis, 
and it had been administered to 
six healthy volunteers. Another 
two, who received a placebo,  
had not become ill. Previous 
animal tests had reportedly  
given no indication of possible 
toxicity.
 The Independent weighed 
in with a curious item headed “German drug company had 
never tested its products on 
humans before.” It emphasised 
that Parexel, commissioned by 
TeGenero to conduct the trial, 
had been refused permission 
to do so in Germany. But the 
article later explained that 
permission had been given after 
protocol changes, though by then 
arrangements had been agreed 
with Northwick Park. 
 Most newspapers provided 
competent summaries of the 
sequence of tests and trials 
used to evaluate new medicines. 
They also explained the role 
of the UK’s Medicines and 
Healthcare Products Regulatory 
Agency (MHRA), which had Hyper: The plight of the 
drug-trial volunteers made 
headline news across the 
media. The Sun newspaper 
acquired exclusive rights 
to some of the stories of 
volunteers involved and 
gave an early account of 
the experiences of one of 
the subjects who received 
a placebo dose and 
witnessed the rapid onset 
of illness in those that had 
received the drug. A later 
report in the newspaper 
at the end of last month 
gave a first-hand account 
of one of the subjects who 
had received the drug, and 
recounted his alarm at the 
rapid onset of symptoms. 
A press release from the 
Northwick Park Hospital 
on March 31, flagged to be 
the last on the condition of 
the volunteers, announced 
that four had improved 
 sufficiently to be allowed 
home. The fifth patient 
is out of critical care and 
making steady recovery 
 under close observation 
and the sixth remains 
in critical care but is 
 conscious and doctors 
are encouraged by his 
progress.
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clinical trial authorisation and 
also reviewed the data submitted 
with the original application for 
authorisation.
 The most comprehensive 
coverage came in The Times. Just 
one day after the initial disclosure, 
it allocated four pages to the 
latest news from the hospital plus 
a detailed review of monoclonal 
antibody technology and therapy, 
an account of how clinical trials 
are organised and material about 
measures normally taken to 
combat the type of total organ 
failure suffered by some of the 
victims.
Heralding these pieces, 
however, was an article by Health 
Editor Nigel Hawkes, headed 
“Drug Trial Ignored Guideline  
On Safety”, which argued that the 
study did not conform to  
best medical practice. “Senior 
doctors expressed concern 
that all six were given the same 
dose…at the same time,”  
Hawkes wrote. “According to 
the standard medical text, trials 
of this sort should avoid giving 
all the doses simultaneously. 
The Textbook of Pharmaceutical 
Medicine specifically gives 
warning that such practices can 
be ‘very difficult to manage’ and ‘put subjects at unnecessary 
risk.’”
At this stage, there was 
confusion regarding the results of 
animal tests with TGN 1412. But 
then The Mail on Sunday claimed 
that “the drug at the centre 
of the ‘elephant man’ testing 
scandal caused monkeys’ necks 
to swell up before it was used 
on humans…At least one of the 
mammals tested with the drug…
suffered swelling of the lymph 
nodes.” The newspaper cited as 
the source of its information the 
Paul Ehrlich Institute, “the health 
ministry body that controls all 
research on biological drugs in 
Germany”. The Lancet (25 March) 
later announced that preclinical 
trials had been conducted in 
rabbits and 20 monkeys, two of 
which showed a transient increase 
in lymph node size.
The Times, however, argued 
that animal tests “create a false 
sense of security”. One reason 
in this case was that an animal’s 
immune system would perceive a 
humanised antibody such as TGN 
1412 as foreign and try to reject it 
before it could exert its full effect. 
In addition, experimental animals 
would not carry the specific 
proteins to which the antibody 
was directed in the human body.An unexpected twist to the 
story at this stage came in The 
Guardian under the headline 
“Interest surges in trials despite 
patients’ plight”. The article 
explained that the Medical 
Research Council and other 
bodies were being “inundated 
with people wanting to sign up for 
drug trials despite the disastrous 
tests at Northwick Park…There 
has been a surge of interest from 
people keen to take part in trials 
and enquiring about the payments 
they can receive.”
 Nearly three weeks after 
the original revelations, press 
reports indicated that two of 
the volunteers had recovered 
sufficiently to return home. At 
that stage, however, there was 
no clarification of whether the 
incident had been attributable 
to contamination of the material 
administered, to its poor quality, 
to a departure from the agreed 
protocol regarding dosage 
and timing or to an entirely 
unpredictable adverse reaction. 
Investigation by the MHRA (and 
by the police) may provide the 
answer.
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